This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The primary goal of the High Throughput Screening Core (HTS) at the University of Kansas (KU) has been to make modern drug discovery tools available to biomedical researchers in the Greater Kansas City area, Kansas and beyond. The modern 4,500 sq. ft. HTS research/office complex is fully equipped with state-of-the-art instrumentation, and includes separate cell culture laboratories as well as a high content screening microscopy laboratory. Personnel have extensive experience in executing cell-based, biochemical, label-free, siRNA as well as high content screening campaigns. The HTS Core assists the drug discovery research community, from assay development to screening to compound profiling and data mining. The instrumentation available in the HTS Core allows us to screen about 100,000 compounds in two days for end point assays, or one week for kinetic assays. We have supported investigators not only from KU and the KU Medical Center, but also from Kansas State University, the University of Missouri, the University of Nebraska and several other institutions in the United States. We are also supporting drug discovery research efforts at non-academia, such as Eli Lilly, InVitria, Wake Forest Institute for Regenerative Medicine and Myelin research Foundation. Over the years, we have provided services for several research projects involving assay development, high throughput screening and data analyses. The HTS Core provides pilot data in support of grant applications by the investigators. At present, the HTS Core is even more actively engaged in advancing drug discovery projects within KU as evidenced by the growing number of active projects and consultations on HTS-ready assay development.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Center Core Grants (P30)
Project #
5P30RR030926-02
Application #
8364921
Study Section
Special Emphasis Panel (ZRR1-RI-2 (01))
Project Start
2011-06-01
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
2
Fiscal Year
2011
Total Cost
$146,683
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Yu, Jia; Lan, Lan; Lewin, Seth J et al. (2017) Identification of novel small molecule Beclin 1 mimetics activating autophagy. Oncotarget 8:51355-51369
Gold, Ben; Smith, Robert; Nguyen, Quyen et al. (2016) Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. J Med Chem 59:6027-44
Gowthaman, Ragul; Miller, Sven A; Rogers, Steven et al. (2016) DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites. J Med Chem 59:4152-70
Wu, Xiaoqing; Lan, Lan; Wilson, David Michael et al. (2015) Identification and validation of novel small molecule disruptors of HuR-mRNA interaction. ACS Chem Biol 10:1476-84
Lan, Lan; Appelman, Carl; Smith, Amber R et al. (2015) Natural product (-)-gossypol inhibits colon cancer cell growth by targeting RNA-binding protein Musashi-1. Mol Oncol 9:1406-20
Shishido, Stephanie N; Delahaye, Adélaïde; Beck, Amanda et al. (2014) The anticancer effect of PQ1 in the MMTV-PyVT mouse model. Int J Cancer 134:1474-83
Shishido, Stephanie N; Prasain, Keshar; Beck, Amanda et al. (2013) Bioavailability and efficacy of a gap junction enhancer (PQ7) in a mouse mammary tumor model. PLoS One 8:e67174
Johnson, David K; Karanicolas, John (2013) Druggable protein interaction sites are more predisposed to surface pocket formation than the rest of the protein surface. PLoS Comput Biol 9:e1002951
Kambhampati, Suman; Rajewski, Roger A; Tanol, Mehmet et al. (2013) A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. Mol Cancer Ther 12:255-63
Diaz, Francisco J; McDonald, Peter R; Roy, Anuradha et al. (2013) Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays. Comb Chem High Throughput Screen 16:168-79

Showing the most recent 10 out of 19 publications